Immune Therapeutics Inc. | Income Statement
Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
-
-
16.20
3.50
-
113.50
Cost of Goods Sold (COGS) incl. D&A
2,853.40
2,879.30
-
-
0.80
49.40
Gross Income
2,853.40
2,879.30
-
-
0.80
64.10
SG&A Expense
93,128.00
30,727.90
9,951.80
9,543.10
5,322.90
4,148.90
EBIT
95,981.50
33,607.20
10,576.50
9,541.20
5,323.80
4,084.80
Unusual Expense
8,641.00
15,942.00
6,101.90
6,831.30
1,393.70
2,981.40
Non Operating Income/Expense
0.20
0.80
-
-
-
-
Interest Expense
1,437.40
388.20
271.00
3,446.60
1,217.00
1,183.20
Pretax Income
106,060.10
49,938.20
16,949.50
19,819.00
7,934.40
8,625.60
Consolidated Net Income
106,060.10
49,938.20
16,949.50
19,819.00
7,934.40
8,625.60
Net Income
106,060.10
48,253.20
16,313.80
19,521.40
7,316.20
8,175.20
Net Income After Extraordinaries
106,060.10
48,253.20
16,313.80
19,521.40
7,316.20
8,175.20
Net Income Available to Common
106,060.10
48,253.20
16,313.80
19,521.40
7,316.20
8,175.20
EPS (Basic)
1.85
0.49
0.11
0.09
0.02
0.02
Basic Shares Outstanding
57,234.30
98,508.50
153,247.00
216,688.00
320,721.10
429,662.40
EPS (Diluted)
1.85
0.49
0.11
0.09
0.02
0.02
Diluted Shares Outstanding
57,234.30
98,508.50
153,247.00
216,688.00
320,721.10
429,662.40
EBITDA
93,128.00
30,727.90
9,981.80
9,539.60
5,322.90
4,083.10
Other Operating Expense
-
-
46.20
-
-
-
Minority Interest Expense
-
1,685.00
635.70
297.60
618.20
450.40
About Immune Therapeutics
View Profile
